Literature DB >> 27019424

Correction: Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients.

Eiichiro Nagata, Mieko Ogino, Kounosuke Iwamoto, Yasuhisa Kitagawa, Yasuo Iwasaki, Fumihito Yoshii, Joh-E Ikeda.

Abstract

Entities: Chemical Disease Species

Year: 2016 PMID： 27019424 PMCID： PMC4809614 DOI： 10.1371/journal.pone.0152845

Source DB: PubMed Journal: PLoS One ISSN： 1932-6203 Impact factor: 3.240

× No keyword cloud information.

Notice of Republication

This article was republished on March 14, 2016, to correct the captions of Figs 3–7 and Figs 9–10 and figure citations in the Discussion section. Please download this article again to view the correct version. The originally published, uncorrected article and the republished, corrected articles are provided here for reference.

Originally published, uncorrected article.

(PDF) Click here for additional data file.

Republished, corrected article.

(PDF) Click here for additional data file.

1 in total

1. Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients.

Authors: Eiichiro Nagata; Mieko Ogino; Kounosuke Iwamoto; Yasuhisa Kitagawa; Yasuo Iwasaki; Fumihito Yoshii; Joh-E Ikeda
Journal: PLoS One Date: 2016-02-24 Impact factor: 3.240

1 in total